Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug 30;2013(8):CD001245.
doi: 10.1002/14651858.CD001245.pub2.

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage

Merih I Baharoglu  1 , Menno R Germans, Gabriel J E Rinkel, Ale Algra, Marinus Vermeulen, Jan van Gijn, Yvo B W E M Roos
Affiliations
Meta-Analysis

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage

Merih I Baharoglu et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Rebleeding is an important cause of death and disability in people with aneurysmal subarachnoid haemorrhage. Rebleeding is probably related to dissolution of the blood clot at the site of aneurysm rupture by natural fibrinolytic activity. This review is an update of a previously published Cochrane review.

Objectives: To assess the effects of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage.

Search methods: We searched the Cochrane Stroke Group Trials Register (February 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 1), MEDLINE (1948 to December 2012), and EMBASE (1947 to December 2012). In an effort to identify further published, unpublished, and ongoing studies we searched reference lists and trial registers, performed forward tracking of relevant references and contacted drug companies.

Selection criteria: Randomised trials comparing oral or intravenous antifibrinolytic drugs (tranexamic acid, epsilon amino-caproic acid, or an equivalent) with control in people with subarachnoid haemorrhage of suspected or proven aneurysmal cause.

Data collection and analysis: Two review authors independently selected trials for inclusion and extracted the data. Three review authors assessed trial quality. For the primary outcome we converted the outcome scales between good and poor outcome for the analysis. We scored death from any cause and rates of rebleeding, cerebral ischaemia, and hydrocephalus per treatment group. We expressed effects as risk ratios (RR) with 95% confidence intervals (CI). We used random-effects models for all analyses.

Main results: We included 10 trials involving 1904 participants. The risk of bias was low in six studies. Four studies were open label and were rated as high risk of performance bias. One of these studies was also rated as high risk for attrition bias. Four trials reported on poor outcome (death, vegetative state, or severe disability) with a pooled risk ratio (RR) of 1.02 (95% confidence interval (CI) 0.91 to 1.15). All trials reported on death from all causes with a pooled RR of 1.00 (95% CI 0.85 to 1.18). In a trial that combined short-term antifibrinolytic treatment (< 72 hours) with preventative measures for cerebral ischaemia the RR for poor outcome was 0.85 (95% CI 0.64 to 1.14). Antifibrinolytic treatment reduced the risk of re-bleeding reported at the end of follow-up (RR 0.65, 95% CI 0.44 to 0.97; 78 per 1000 participants), but there was heterogeneity (I² = 62%) between the trials. The pooled RR for reported cerebral ischaemia was 1.41 (95% CI 1.04 to 1.91, 83 per 1000 participants), again with heterogeneity between the trials (I² = 52%). Antifibrinolytic treatment showed no effect on the reported rate of hydrocephalus in five trials (RR 1.11, 95% CI 0.90 to 1.36).

Authors' conclusions: The current evidence does not support the use of antifibrinolytic drugs in the treatment of people with aneurysmal subarachnoid haemorrhage, even in those who have concomitant treatment strategies to prevent cerebral ischaemia. Results on short-term treatment are promising, but not conclusive. Further randomised trials evaluating short-term antifibrinolytic treatment are needed to evaluate its effectiveness.

PubMed Disclaimer

Conflict of interest statement

Some authors (YBWEMR, GJER, MV) participated in one of the two largest trials included in this review (Roos 2000a; Vermeulen 1984), which were co‐ordinated by two of the current review authors. MRG has written a protocol for a new trial (Verbaan 2012). None of the review authors have any financial or other commercial conflict of interest to disclose.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
See this image and copyright information in PMC

Update of

Comment in

References

References to studies included in this review

Chandra 1978 {published data only}
    1. Chandra B. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double‐blind clinical trial. Annals of Neurology 1978;3:502‐4. [MEDLINE: ] - PubMed
Fodstad 1981 {published data only}
    1. Fodstad H, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery 1981;8:158‐65. [MEDLINE: ] - PubMed
Girvin 1973 {published and unpublished data}
    1. Girvin JP. The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association 1973;98:150‐2. [MEDLINE: ] - PubMed
Hillman 2002 {published data only}
    1. Hillman J, Fridriksson S, Nillson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery 2002;97:771‐8. [MEDLINE: ] - PubMed
Kaste 1979 {published data only}
    1. Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double‐blind study. Stroke 1979;10:519‐22. [MEDLINE: ] - PubMed
Maurice 1978 {published data only}
    1. Maurice‐Williams RS. Prolonged antifibrinolysis: an effective non‐surgical treatment for ruptured intracranial aneurysms?. British Medical Journal 1978;1:945‐7. [MEDLINE: ] - PMC - PubMed
Roos 2000a {published and unpublished data}
    1. Roos Y, for the STAR‐study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo‐controlled trial. Neurology 2000;54:77‐82. [MEDLINE: ] - PubMed
Tsementzis 1990 {published data only}
    1. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double‐blind placebo‐controlled study. Acta Neurochirurgica 1990;102:1‐10. [MEDLINE: ] - PubMed
    1. Tsementzis SA, Honan WP, Nightingale S, Hitchcock ER, Meyer CH. Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica 1990;103:116‐21. - PubMed
Van Rossum 1977 {published data only}
    1. Rossum J, Wintzen AR, Endtz LJ, Schoen JH, Jonge H. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double‐blind controlled clinical trial. Annals of Neurology 1977;2:238‐42. [MEDLINE: ] - PubMed
Vermeulen 1984 {published data only}
    1. Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine 1984;311:432‐7. [MEDLINE: ] - PubMed

References to studies excluded from this review

Adams 1981 {published data only}
    1. Adams HP Jr, Nibbelink DW, Torner JC, Sahs AL. Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study. Archives of Neurology 1981;38:25‐9. [MEDLINE: ] - PubMed
Ameen 1981 {published data only}
    1. Ameen AA, Illingworth R. Anti‐fibrinolytic treatment in the pre‐operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. Journal of Neurology, Neurosurgery and Psychiatry 1981;44:220‐6. [MEDLINE: ] - PMC - PubMed
Brzecki 1974 {published data only}
    1. Brzecki A, Misztal S. Results of Trasylol treatment of subarachnoid hemorrhage [Wyniki leczenia Trasylolem krwotoku podpajeczynowkowego]. Polski Tygodnik Lekarski 1974;29(2):53‐5. [MEDLINE: ] - PubMed
Buchner 1985 {published data only}
    1. Buchner H, Hacke W, Kugel I, Zeumer H, Ferbert A. Antifibrinolytic therapy following an aneurysmal subarachnoid hemorrhage [Antifibrinolytika in der konservativen Therapie der aneurysmatischen Subarachnoidalblutung]. Intensivmed 1985;22:424‐7.
Chowdhary 1979 {published data only}
    1. Chowdhary UM, Carey PC, Hussein MM. Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon‐aminocaproic acid. Lancet 1979;1:741‐3. [MEDLINE: ] - PubMed
Chowdhary 1981 {published data only}
    1. Chowdhary UM, Sayed K. Comparative clinical trial of epsilon amino‐caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry 1981;44:810‐3. [MEDLINE: ] - PMC - PubMed
Chowdhary 1986 {published data only}
    1. Chowdhary UM, Sayed K. Prevention of early recurrence of aneurysmal subarachnoid haemorrhage by tranexamic acid: a controlled clinical trial. Vascular Surgery 1986;1:8‐13. [EMBASE: 1986195828]
Fodstad 1978 {published data only}
    1. Fodstad H, Liliequist B, Schannong M, Thulin CA. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surgical Neurology 1978;10:9‐15. [MEDLINE: ] - PubMed
Gelmers 1980 {published data only}
    1. Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochirurgica 1980;52:45‐50. [MEDLINE: ] - PubMed
Gibbs 1971 {published data only}
    1. Gibbs JR, Corkill AG. Use of an anti‐fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms. Postgraduate Medical Journal 1971;47:199‐200. [MEDLINE: ] - PMC - PubMed
Kassell 1984 {published data only}
    1. Kassell NF, Torner JC, Adams HP. Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the Cooperative Aneurysm Study. Journal of Neurosurgery 1984;61:225‐30. [MEDLINE: ] - PubMed
Knuckey 1982 {published data only}
    1. Knuckey NW, Stokes BA. Medical management of patients following a ruptured cerebral aneurysm, with epsilon‐aminocaproic acid, kanamycin, and reserpine. Surgical Neurology 1982;17:181‐5. [MEDLINE: ] - PubMed
Marchel 1992 {published data only}
    1. Marchel A. Antifibrinolytic treatment after subarachnoid hemorrhage. Neurologia i Neurochirurgia Polska 1992;26:502‐10. [MEDLINE: ] - PubMed
Nibbelink 1975 {published data only}
    1. Nibbelink DW, Torner JC, Henderson WG. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke 1975;6:622‐9. [MEDLINE: ] - PubMed
Profeta 1975 {published data only}
    1. Profeta G, Castellano F, Guarnieri L, Cigliano A, Amborsio A. Antifibrinolytic therapy in the treatment of subarachnoid haemorrhage caused by arterial aneurysms. Journal of Neurosurgical Sciences 1975;19:77‐8. [MEDLINE: ] - PubMed
Rosenorn 1988 {published data only}
    1. Rosenorn J, Eskesen V, Espersen JO, Haase J, Schmidt K. Antifibrinolytic therapy in patients with aneurysmal subarachnoid haemorrhage. British Journal of Neurosugery 1988;2:447‐53. [MEDLINE: ] - PubMed
Salaschek 1983 {published data only}
    1. Salaschek M, Weinrich W. Epsilon aminocaproic acid (FACA) in the treatment of spontaneous subarachnoid haemorrhage [Antifibrinolytische behandlung spontaner subarachnoidalblutungen mit epsilon‐aminocapronaure]. Aktuelle Neurologie 1983;10:65‐8. [EMBASE: 1983183434]
Sengupta 1976 {published data only}
    1. Sengupta RP, So SC, Villarejo Ortega FJ. Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. Journal of Neurosurgery 1976;44:479‐84. [MEDLINE: ] - PubMed
Shucart 1980 {published data only}
    1. Shucart WA, Hussain SK, Cooper PR. Epsilon‐aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. Journal of Neurosurgery 1980;53:28‐31. [MEDLINE: ] - PubMed
Starke 2008 {published data only}
    1. Starke RM, Kim GH, Fernandez A, Komotar RJ, Hickman ZL, Otten ML, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008;39:2617‐21. [MEDLINE: ] - PubMed
Wijdicks 1989 {published data only}
    1. Wijdicks EF, Hasan D, Lindsay KW, Brouwers PJ, Hatfield R, Murray GD, et al. Short‐term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage. Stroke 1989;20:1674‐9. [MEDLINE: ] - PubMed

References to ongoing studies

Verbaan 2012 {published data only}
    1. Verbaan D. Ultra‐early tranexamic acid after subarachnoid hemorrhage. Netherlands Trial Register 2012. - PMC - PubMed

Additional references

Adams 1982
    1. Adams HP. Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage. Stroke 1982;13:256‐9. [MEDLINE: ] - PubMed
Adams 1987
    1. Adams HP. Antifibrinolytics in aneurysmal subarachnoid hemorrhage. Do they have a role? Maybe. Archives of Neurology 1987;44:114‐5. [MEDLINE: ] - PubMed
Biller 1988
    1. Biller J, Godersky JC, Adams HP. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1300‐5. [MEDLINE: ] - PubMed
Carley 2005
    1. Carley S, Sen A. Best evidence topic report. Antifibrinolytics for the initial management of sub arachnoid haemorrhage. Emergency Medicine Journal 2005;22:274‐5. [MEDLINE: ] - PMC - PubMed
Chawjol 2008
    1. Chawjol M, Starke RM, Kim GH, Majer SA, Connolly ES. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocritical Care 2008;8:418‐26. [MEDLINE: ] - PubMed
Connolly 2012
    1. Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:1711‐37. [MEDLINE: ] - PubMed
Fodstad 1982
    1. Fodstad H. Antifibrinolytic treatment in subarachnoid haemorrhage: present state. Acta Neurochirurgica 1982;63:233‐44. [MEDLINE: ] - PubMed
Gaberel 2012
    1. Gaberel T, Magheru C, Emery E, Derlon J. Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta‐analysis. Acta Neurochirurgica 2012;154:1‐9. [MEDLINE: ] - PubMed
Gibbs 1967
    1. Gibbs JR, O'Gorman P. Fibrinolysis in subarachnoid haemorrhage. Postgraduate Medical Journal 1967;43(506):779‐84. [MEDLINE: ] - PMC - PubMed
Guo 2011
    1. Guo L, Zhou H, Xu J, Wang Y, Qiu Y, Jiang J. Risk factors related to aneurysmal rebleeding. World Neurosurgery 2011;76:292‐8. [MEDLINE: ] - PubMed
Harrigan 2010
    1. Harrigan MR, Rajneesh KF, Ardelt AA, Fisher WS. Short‐term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus. Neurosurgery 2010;67:935‐9. [MEDLINE: ] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Lindsay 1987
    1. Lindsay KW. Antifibrinolytic agents in subarachnoid haemorrhage. Journal of Neurology 1987;234:1‐8. [MEDLINE: ] - PubMed
Locksley 1966
    1. Locksley HB. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Journal of Neurosurgery 1966;25:321‐68. [MEDLINE: ] - PubMed
Maira 2006
    1. Maira G, Albanese A, Pentimalli L, Tirpakova B. Treatment of intracranial aneurysms. Clinical and Experimental Hypertension 2006;28:371‐6. [MEDLINE: ] - PubMed
Mayberg 1994
    1. Mayberg MR, Batjer HH, Dacey R, Diringer M, Haley EC, Heros RC, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1994;90:2592‐605. [MEDLINE: ] - PubMed
Naidech 2005
    1. Naidech AM, Janjua N, Kreiter KT, Ostapkovich ND, Fitzsimmons BF, Parra A, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Archives of Neurology 2005;62:410‐6. - PubMed
Ramirez 1981
    1. Ramirez‐Lassepas M. Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm. Neurology 1981;31:316‐22. [MEDLINE: ] - PubMed
RevMan 2012 [Computer program]
    1. The NordicCochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The NordicCochrane Centre, The Cochrane Collaboration, 2012.
Rinkel 2008
    1. Rinkel GJ. Medical management of patients with aneurysmal subarachnoid haemorrhage. International Journal of Stroke 2008;3:193‐204. [MEDLINE: ] - PubMed
Roos 2000b
    1. Roos YB, Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. Journal of Neurology, Neurosurgery and Psychiatry 2000;68:337‐41. [MEDLINE: ] - PMC - PubMed
Van Gijn 2001
    1. Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001;124:249‐78. [MEDLINE: ] - PubMed
Van Gijn 2007
    1. Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007;369:306‐18. [MEDLINE: ] - PubMed
Vermeulen 1980
    1. Vermeulen M, Muizelaar JP. Do antifibrinolytic agents prevent rebleeding after rupture of a cerebral aneurysm? A review. Clinical Neurology and Neurosurgery 1980;82:25‐30. [MEDLINE: ] - PubMed
Vermeulen 1983
    1. Vermeulen M, Gijn J, Blijenberg BG. Spectrophotometric analysis of CSF after subarachnoid hemorrhage: limitations in the diagnosis of rebleeding. Neurology 1983;33:112‐4. [MEDLINE: ] - PubMed
Vermeulen 1996
    1. Vermeulen M. Subarachnoid haemorrhage: diagnosis and treatment. Journal of Neurology 1996;243:496‐501. [MEDLINE: ] - PubMed
Weaver 1994
    1. Weaver JP, Fisher M. Subarachnoid hemorrhage: an update of pathogenesis, diagnosis and management. Journal of the Neurological Sciences 1994;125:119‐31. [MEDLINE: ] - PubMed
Weir 1987
    1. Weir B. Antifibrinolytics in subarachnoid hemorrhage. Do they have a role? No. Archives of Neurology 1987;44:116‐8. [MEDLINE: ] - PubMed

References to other published versions of this review

Roos 1998
    1. Roos YB, Vermeulen M, Rinkel GJ, Algra A, Gijn J, Algra A. Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry 1998;65:942‐3. [MEDLINE: ] - PMC - PubMed
Roos 2003
    1. Roos YB, RinkelGJE, VermeulenM, Algra A, vanGijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD001245] - DOI - PubMed

Publication types

MeSH terms